← Eichor
Condition: Recurrent And Metastatic Nasopharyngeal Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Recurrent And Metastatic Nasopharyngeal Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT07325539Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant R
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT06259721Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
NA · 1 location(s) · Affiliated Hospital of Nantong University · NCT06389201A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06629597Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Tr
Phase 2 · 6 location(s) · Ming-Yuan Chen · NCT07070479Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06197776Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metast
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07705243Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06657690Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta
Phase 2 · 88 location(s) · National Cancer Institute (NCI) · NCT06029270A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Phase 1/Phase 2 · 20 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07258979A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance
Phase 2 · 15 location(s) · Shanghai Henlius Biotech · NCT06839066SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After
Phase 2 · 2 location(s) · The First Affiliated Hospital of Xiamen University · NCT06676722Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Phase 2 · 2 location(s) · Shanghai Institute Of Biological Products · NCT06194656Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic H
Phase 1 · 1 location(s) · West China Hospital · NCT07625423EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06802835Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Phase N/A · 4 location(s) · Vanderbilt University Medical Center · NCT00898638A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Me
Phase 3 · 1 location(s) · Shanghai Miracogen Inc. · NCT06976190Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Ming-Yuan Chen · NCT07581821A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcin
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06437522A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemothera
Phase 2/Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06241599Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06509009Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objective
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT01365169SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06323239Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
Phase 3 · 1 location(s) · Fudan University · NCT06177301Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi
NA · 1 location(s) · Emory University · NCT06662058The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Phase 2 · 3 location(s) · Chongqing University Cancer Hospital · NCT04830267Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05854849Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Phase 2 · 1 location(s) · Ming-Yuan Chen · NCT06472713
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.